Is Scilex Holding Company going out of business?

Scilex Holding Company (SCLX) Fundamentals

A quick summary of the latest filed figures while the full analysis loads.

Scilex Holding Company (SCLX) scores 19 out of 100 on fundamentals, Distressed / Caution, based on SEC filing data.

Leading signal: Shares dilution YoY: Reverse split detected; adjusted share change (-40.5% YoY) and the capital-structure risk is penalized.

Five questions, kept separate

Survival - Funding dependent

Recent free cash flow is positive, so there is no current cash-burn countdown. Debt pressure is the other decisive risk.

Business quality - Pre-commercial

Operating margins cannot grade a pipeline; Survival and clinical evidence remain the relevant lenses here.

Trajectory - Clinical progress unavailable

Fundamentals can show funding and burn, but not whether the clinical pipeline is advancing.

Valuation - Demanding

-252% net-cash backing support a demanding pre-commercial Valuation assessment.

Event risk - Evidence unavailable

No active asserted adverse event was found in the available filing evidence. The filing evidence is stale or incomplete, so this is not proof of absence.

What the rules read

• Shares dilution YoY: Reverse split detected; adjusted share change (-40.5% YoY) and the capital-structure risk is penalized.
• Debt / Equity: Negative equity (balance sheet deficit; monitor solvency)
• Revenue CAGR (3Y): -7.35%
• R&D intensity: 34.53%
• Revenue growth YoY: -22.78% (YoY)
• Cash Runway (years): Self-funded
• Return on Assets: -147.52%
• FCF margin: 12.17%
• Debt Maturity Runway: 0% long-term (Near-term refinancing risk)
• Price / Sales: 1.4x (see Valuation)
• Price / Earnings: Unprofitable (see Valuation)
• Operating leverage: -275.0%

Read from filings through 2026-08-14.

Price as of 2026-09-09.